CD44 and hepatocellular carcinoma: IC-2, a novel small-molecule Wnt inhibitor, reduced the population of CD44+ cells (liver CSCs) and the sphere-forming ability of hepatocellular carcinoma (HCC) cells, as well as in CRC and bladder cancer cells [152].